|
- Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments
- Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session
SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th Radiological Society of North America (RSNA 2025) and presented real-world clinical use cases of its key brain imaging analysis AI solutions.
At the conference, Neurophet showcased its software 'Neurophet AQUA AD,' which supports monitoring of Alzheimer's disease treatment prescription, therapeutic response, and potential adverse effects. Neurophet AQUA AD provides precise brain imaging analysis throughout the administration of anti-amyloid antibody therapies by quantitatively analyzing magnetic resonance imaging (MRI) and positron emission tomography (PET) scans.
In addition, real-world clinical use cases of Neurophet AQUA AD were demonstrated during the AI Theater session held in the exhibition hall. In this session, Professor Chong Hyun Suh from the Department of Radiology at Asan Medical Center, University of Ulsan College of Medicine, delivered a lecture titled "AI-Powered Monitoring of Amyloid-Related Imaging Abnormalities in Anti-Amyloid Therapy: Neurophet AQUA AD."
Professor Suh introduced AI-based ARIA detection and quantification technologies that address the limitations of conventional manual approaches. He also elaborated how AI enhances the safety and clinical effectiveness of anti-amyloid therapies by presenting various real-world clinical cases in which patients receiving Alzheimer's disease treatments developed ARIA.
Through booth exhibition, Neurophet also presented Neurophet AQUA AD alongside its other solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software, and Neurophet SCALE PET, a PET imaging quantification software.
The company highlighted the technological excellence of Neurophet AQUA MS, which was first unveiled at last year's RSNA. Neurophet AQUA MS is a software module integrated into Neurophet AQUA that analyzes brain images of patients with multiple sclerosis, a refractory central nervous system disorder. The solution received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October of last year.
Jake Junkil Been, Co-CEO of Neurophet, stated, "Neurophet AQUA AD has been gaining significant attention from major domestic and global companies in the field of imaging analysis for Alzheimer's disease treatment planning. Through partnerships with global medical device companies at RSNA 2025, we plan to accelerate the expansion of our key products in the North American market."
Meanwhile, RSNA 2025 is the world's largest radiology conference, attended by radiologists and global medical device industry professionals, and is held annually in Chicago, USA. This year's conference took place from November 30 to December 4 (local time).
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
- Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments
- Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session
SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th Radiological Society of North America (RSNA 2025) and presented real-world clinical use cases of its key brain imaging analysis AI solutions.
At the conference, Neurophet showcased its software 'Neurophet AQUA AD,' which supports monitoring of Alzheimer's disease treatment prescription, therapeutic response, and potential adverse effects. Neurophet AQUA AD provides precise brain imaging analysis throughout the administration of anti-amyloid antibody therapies by quantitatively analyzing magnetic resonance imaging (MRI) and positron emission tomography (PET) scans.
In addition, real-world clinical use cases of Neurophet AQUA AD were demonstrated during the AI Theater session held in the exhibition hall. In this session, Professor Chong Hyun Suh from the Department of Radiology at Asan Medical Center, University of Ulsan College of Medicine, delivered a lecture titled "AI-Powered Monitoring of Amyloid-Related Imaging Abnormalities in Anti-Amyloid Therapy: Neurophet AQUA AD."
Professor Suh introduced AI-based ARIA detection and quantification technologies that address the limitations of conventional manual approaches. He also elaborated how AI enhances the safety and clinical effectiveness of anti-amyloid therapies by presenting various real-world clinical cases in which patients receiving Alzheimer's disease treatments developed ARIA.
Through booth exhibition, Neurophet also presented Neurophet AQUA AD alongside its other solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software, and Neurophet SCALE PET, a PET imaging quantification software.
The company highlighted the technological excellence of Neurophet AQUA MS, which was first unveiled at last year's RSNA. Neurophet AQUA MS is a software module integrated into Neurophet AQUA that analyzes brain images of patients with multiple sclerosis, a refractory central nervous system disorder. The solution received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October of last year.
Jake Junkil Been, Co-CEO of Neurophet, stated, "Neurophet AQUA AD has been gaining significant attention from major domestic and global companies in the field of imaging analysis for Alzheimer's disease treatment planning. Through partnerships with global medical device companies at RSNA 2025, we plan to accelerate the expansion of our key products in the North American market."
Meanwhile, RSNA 2025 is the world's largest radiology conference, attended by radiologists and global medical device industry professionals, and is held annually in Chicago, USA. This year's conference took place from November 30 to December 4 (local time).
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'
HONG KONG, Jan. 25, 2026 /PRNewswire/ -- With the Hong Kong Government's official implementation of the new vehicle seat belt legislation from 25 January 2026, further enhancing road and passenger safety, Kwoon Chung Bus Holdings Limited ("Kwoon Chung Bus") is pleased to announce that most of the buses under the Group have already been fully equipped with seat belts for passenger seats, in full compliance with the new statutory requirements. The Group continues to uphold its core safety culture of "Safety, We Care", reinforcing passenger and journey protection through a holistic approach encompassing systems, training, and technology.
As one of the largest non‑franchised bus operators in Hong Kong, Kwoon Chung Bus has, over the years, regarded safety as an integral part of its corporate culture and daily operations. The Group firmly believes that truly sustainable safety does not rely solely on equipment or regulatory compliance, but is rooted in the care and sense of responsibility demonstrated by every employee in their day‑to‑day work.
Mr Wong Leung Pak, Matthew, SBS, Chairman of Kwoon Chung Bus Holdings Limited, said: "Safety, We Care" is not merely a slogan, but a safety culture that Kwoon Chung Bus has established and practised over the years. Through systems, training and technology, we integrate safety into daily operations, enhancing driving safety from a preventive perspective and ensuring that every passenger can complete their journey with peace of mind."
Building on this established safety culture, Kwoon Chung Bus is progressively introducing AI-powered smart video recording systems to support management teams in monitoring and analysing driving conditions, enabling more effective identification of potential risks and timely follow‑up actions.
Turning Care into Action - Strengthening Daily Safety Management
The development and optimisation of the AI smart recording system has been ongoing for nearly a decade. Currently, more than half of the Group's fleet has been equipped, with full deployment across the entire fleet targeted for completion by the end of 2026. Through onboard cameras and real‑time analysis, the system can identify inattentive or high‑risk driving behaviours and issue immediate alerts to drivers, reducing risks at source.
When abnormal or irregular driving behaviour is detected, alerts are promptly issued within the vehicle, while relevant footage is simultaneously uploaded to a cloud platform for analysis and follow‑up by Kwoon Chung Bus's Training & Performance Management Department, in accordance with established procedures. Where necessary, the control centre will contact the driver based on the assessed risk level to conduct performance reviews and improvement measures, ensuring that the safety culture is effectively implemented across every operational link.
Long‑Term Development: Advancing Smart Safety Management
through Data‑Driven Innovation
Looking ahead, Kwoon Chung Bus will continue to collect and analyse local driving data to further train and optimise the system. As big data analytics mature, the Group plans to introduce the "Safe GPT" intelligent safety analysis platform, leveraging artificial intelligence to evaluate historical driving behaviour, identify high‑risk periods and driving weaknesses, and arrange targeted training programmes to prevent incidents at source.
Kwoon Chung Bus reiterates that "Safety, We Care" is a safety culture embedded across systems, technology and employee conduct. The Group will continue to promote safety management in a prudent and systematic manner, providing the public with safe, reliable and high‑quality transportation services.
About Kwoon Chung Bus Holdings Limited
Kwoon Chung Bus Group is one of Hong Kong's largest non-franchised bus companies, dedicated to providing reliable, safe, economical, and comfortable bus services, including franchised buses, non-franchised buses, cross-boundary buses, rehabilitation buses, limousine, and airport transfers. The Group is also actively exploring the application of smart mobility and autonomous driving technologies.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
New Seat Belt Legislation Takes Effect -- Kwoon Chung Bus Fully Compliant Strengthening Passenger and Road Safety through a Safety‑First Culture and AI Smart Driving Management Systems
